{"id":8415,"date":"2019-04-25T06:00:29","date_gmt":"2019-04-25T06:00:29","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-publishes-the-annual-report-for-2018-2\/"},"modified":"2024-11-18T19:05:59","modified_gmt":"2024-11-18T19:05:59","slug":"acarix-publishes-the-annual-report-for-2018-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-publishes-the-annual-report-for-2018-2\/","title":{"rendered":"Acarix publishes the annual report for 2018"},"content":{"rendered":"
<\/strong><\/div>\n

Press release
Malmö, April 25, 2019<\/p>\n

Acarix publishes the annual report for 2018<\/strong><\/p>\n

Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com.<\/p>\n

The Annual Report is also attached to this press release.<\/p>\n

<\/strong><\/p>\n

For further information, please contact:
<\/strong>Per Persson, CEO
E-mail per.persson@acarix.com
Phone: +46 73 600 59 90<\/p>\n

Acarix is listed on Nasdaq First North in Stockholm.
Wildeco Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) is Certified Adviser to Acarix.<\/p>\n

This information is such that Acarix (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 25, 2019 at 08.00 (CET).<\/em><\/p>\n

<\/strong><\/p>\n

About Acarix<\/strong>
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Please visit www.acarix.com<\/a> for more information.<\/p>\n

Acarix Annual Report 2018<\/a>
PR_Acarix Annual Report 2018<\/a><\/p>\n

—
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire<\/em><\/p>\n

<\/div>\n